Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
18
×
life sciences
national blog main
boston top stories
clinical trials
biotech
national top stories
san francisco blog main
fda
boston
new york blog main
deals
new york top stories
amgen
new york
alnylam pharmaceuticals
san francisco top stories
eli lilly
inclisiran
regeneron pharmaceuticals
roche
san diego blog main
sanofi
blueprint medicines
cancer
cancer drugs
investing
novartis
pcsk9 inhibitors
rare disease drugs
rna interference
san diego top stories
alexion pharmaceuticals
alirocumab
avapritinib
cholesterol
drugs
dyne therapeutics
europe blog main
evolocumab
What
drug
18
×
medicines
18
×
fda
ipo
new
genetic
therapeutics
cancer
cholesterol
disease
medco
approval
company
lead
lowering
million
muscle
pharmaceuticals
rare
research
year
ago
alnylam
announced
approved
biotech
blueprint
brings
candidate
data
deal
developing
diseases
dyne
hepatitis
latest
long
medicine
pharma
phase
Language
unset
Current search:
drug
×
" boston blog main "
×
medicines
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines